New York State Assembly

 
•  Summary 
 
•  Actions 
 
•  Committee Votes 
 
•  Floor Votes 
 
•  Memo 
 
•  Text 
 
•  LFIN 
 
•  Chamber Video/Transcript 

A02030 Summary:

A02030 Actions:

A02030 Committee Votes:

Committee:HEALTH   Chair:Gottfried      
DATE:02/02/2021AYE/NAY:26/0  Action: Favorable refer to committee Ways and Means        
Gottfried
Aye
Byrne
Aye
Galef
Aye
McDonough
Aye
Dinowitz
Aye
Byrnes
Aye
Cahill
Aye
Ashby
Aye
Paulin
Aye
Miller
Aye
Cymbrowitz
Aye
Salka
Aye
Gunther
Aye
Jensen
Aye
Rosenthal L 
Aye
Hevesi
Aye
Steck
Aye
Abinanti
Aye
Braunstein
Aye
Solages
Aye
Bichotte Hermel
Aye
Barron
Aye
Sayegh
Aye
Rosenthal D 
Aye
McDonald
Aye
Reyes
Aye

Committee:WAYS AND MEANS   Chair:Weinstein      
DATE:05/11/2021AYE/NAY:28/6  Action: Favorable         
Weinstein
Aye
Ra
Nay
Glick
Aye
Fitzpatrick
Nay
Nolan
Excused
Hawley
Nay
Pretlow
Aye
Montesano
Aye
Perry
Aye
Blankenbush
Nay
Colton
Aye
Norris
Aye
Cook
Aye
Brabenec
Nay
Cahill
Aye
Palmesano
Nay
Aubry
Aye
Byrne
Aye
Cusick
Aye
Ashby
Aye
Benedetto
Aye
Weprin
Aye
Rodriguez
Aye
Ramos
Aye
Braunstein
Aye
McDonald
Aye
Rozic
Aye
Dinowitz
Aye
Joyner
Aye
Magnarelli
Aye
Zebrowski
Aye
Bronson
Aye
Dilan
Aye
Seawright
Aye
Hyndman
Aye

A02030 Floor Votes:

A02030 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
 submitted in accordance with Assembly Rule III, Sec 1(f)



 
BILL NUMBER: A2030
 
SPONSOR: Rosenthal L

 
TITLE OF BILL:
 
An act to amend the social services law and the public health law, in
relation to medication for the treatment of substance use disorders
 
 
PURPOSE:
 
This legislation will expand access to medications that treat substance
use disorders.
 
 
SUMMARY OF SPECIFIC PROVISIONS:
 
Section one amends subdivision 2 of section 365-a of the social services
law by adding a new paragraph (gg)
 
Section two amends subdivision 26-b of section 364-j of the social
services law. Section three amends subdivision 10 of section 273 of the
public health law. Section four sets the effective date.
 
 
JUSTIFICATION:
 
Medication assisted treatment, or MAT, is an evidence-based treatment
method that uses FDA approved medications to help an individual overcome
a substance use disorder. Medications such as methadone, buprenorphine
and naltrexone have all been used successfully and more treatment
providers are turning to this approach given its ability to reduce and
block cravings, ease withdrawal symptoms and otherwise enable an indi-
vidual to reach recovery more easily.  However, medications used in MAT
programs are not interchangeable and each patient may respond different-
ly, therefore it is imperative that this choice be left to the patient
and their doctor to determine the appropriate medication. Under current
law, individuals under Medicaid are not given the opportunity to access
all forms of medication assisted treatment and may be limited to one
specific type. This legislation would allow individuals under Medicaid
the ability to access whichever MAT medication is most beneficial to
them and their needs, without utilization control, mandated prior
authorization, or lifetime limits.
 
 
LEGISLATIVE HISTORY:
 
2019: A.7246-B/S.5935-A - Vetoed
 
 
FISCAL IMPLICATIONS:
 
Undetermined.
 
 
EFFECTIVE DATE:
This act shall take effect in 90 days.

A02030 Text:

 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                          2030
 
                               2021-2022 Regular Sessions
 
                   IN ASSEMBLY
 
                                    January 14, 2021
                                       ___________
 
        Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN,
          SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on
          Health
 
        AN  ACT  to  amend the social services law and the public health law, in
          relation to medication for the treatment of substance use disorders

          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1.  Subdivision 2 of section 365-a of the social services law
     2  is amended by adding a new paragraph (gg) to read as follows:
     3    (gg) all buprenorphine products, methadone or long  acting  injectable
     4  naltrexone  for  detoxification  or maintenance treatment of a substance
     5  use disorder prescribed according to generally accepted national profes-
     6  sional guidelines for the treatment of a substance use disorder.    Such
     7  medication assisted treatment shall not be subject to any prior authori-
     8  zation mandate.
     9    §  2. Subdivision 26-b of section 364-j of the social services law, as
    10  added by section 4 of part B of chapter 69  of  the  laws  of  2016,  is
    11  amended to read as follows:
    12    26-b. Managed care providers shall not require prior authorization for
    13  [an  initial  or  renewal  prescription  for buprenorphine or injectable
    14  naltrexone  for  detoxification  or  maintenance  treatment  of   opioid
    15  addiction  unless  the prescription is for a non-preferred or non-formu-
    16  lary form of the drug or as otherwise required by section 1927(k)(6)  of
    17  the  Social  Security Act] any buprenorphine products, methadone or long
    18  acting injectable naltrexone for detoxification or maintenance treatment
    19  of a substance use disorder prescribed according to  generally  accepted
    20  national  professional  guidelines  for the treatment of a substance use
    21  disorder.
    22    § 3. Subdivision 10 of section  273  of  the  public  health  law,  as
    23  amended  by  section  7 of part GG of chapter 56 of the laws of 2020, is
    24  amended to read as follows:
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD00371-02-1
        A. 2030                             2
 
     1    10. Prior authorization shall not  be  required  for  [an  initial  or
     2  renewal  prescription  for  buprenorphine  or  injectable naltrexone for
     3  detoxification or maintenance treatment of opioid addiction  unless  the
     4  prescription  is  for a non-preferred or non-formulary form of such drug
     5  as  otherwise required by section 1927(k)(6) of the Social Security Act.
     6  Further, prior authorization shall not be required  for]  any  buprenor-
     7  phine products, methadone, [when used for opioid use disorder and admin-
     8  istered  or  dispensed  in  an  opioid treatment program] or long acting
     9  injectable naltrexone for detoxification or maintenance treatment  of  a
    10  substance  use  disorder  prescribed  according  to  generally  accepted
    11  national professional guidelines for the treatment of  a  substance  use
    12  disorder.
    13    §  4.  This  act shall take effect on the ninetieth day after it shall
    14  have become a law; provided, however, that the amendments to subdivision
    15  26-b of section 364-j of the social services law made by section two  of
    16  this  act  shall  not  affect  the  repeal of such section, and shall be
    17  deemed repealed therewith.

A02030 LFIN:

 
NO LFIN

A02030 Chamber Video/Transcript: